Antibody discovery services market seen topping $5 billion by 2030

The Business Research Company says the antibody discovery services market is set to grow from $2.9 billion in 2025 to $3.24 billion in 2026, then reach $5.07 billion by 2030. The forecast points to rising demand for precision medicine, more biologics development and faster adoption of AI and automation in discovery workflows.

Why it matters: - Antibody discovery services speed the development of targeted therapies, diagnostics and research tools. - The market’s growth tracks with broader demand for precision medicine and biologics. - Faster discovery could help drugmakers move more candidates into development with higher specificity.

What happened: - The Business Research Company published a 2030 outlook for the antibody discovery services market on July 15, 2026. - The market is estimated at $2.9 billion in 2025 and projected to reach $3.24 billion in 2026. - The forecast implies 11.6% growth from 2025 to 2026. - The market is projected to reach $5.07 billion by 2030. - The report forecasts a 11.9% CAGR through 2030. - The analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the market report. - View the full antibody discovery services market report.

The details: - Demand is being driven by biologics tailored to specific diseases, monoclonal antibody drug development and outsourcing by pharmaceutical companies. - Hybridoma and phage display methods continue to improve discovery capabilities. - Rising biotechnology research funding is supporting market expansion. - AI-driven drug discovery platforms are expected to add momentum. - Personalized and precision medicines are increasing demand for custom antibodies. - The biologics and biosimilars pipeline is widening. - Automation in antibody screening is becoming more important. - Partnerships between biotechnology firms and contract research organizations are expected to support growth. - Emerging workflows include robotic automation for high-throughput screening, cloud-based bioinformatics for antibody sequence optimization, digital twin modeling for antibody-antigen interactions, and Industry 4.0-enabled smart biolab automation. - The report defines antibody discovery services as specialized research capabilities for finding, producing and refining antibodies for therapeutics, diagnostics and scientific research. - The services are designed to shorten development cycles and improve success rates. - They support the identification of antibodies that bind to disease-related molecules.

Between the lines: - Precision medicine is no longer a niche demand driver; it is becoming a structural market force. - The report’s emphasis on AI, robotics and cloud tools suggests antibody discovery is shifting from a lab-heavy workflow to a more automated data-driven process. - North America led the market in 2025 because of strong biotech infrastructure, research funding and a dense concentration of pharma and biotech companies. - Asia-Pacific is expected to grow fastest as healthcare investment rises and biopharma capabilities expand. - The report cites a February 2024 Personalized Medicine Coalition update showing the FDA approved 16 new personalized therapies for rare disease patients in 2023, up from six in 2022.

What's next: - Biotech firms and CROs are likely to deepen partnerships as demand for faster, more specialized discovery rises. - Automation and AI tools should become more embedded in antibody screening and sequence optimization. - Growth in personalized therapies and biosimilars should keep expanding the addressable market through 2030. - The Business Research Company says its 2026 report additions include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - The Business Research Company also says it offers 30,000+ reports across 27 industries and 60+ geographies, plus its Global Market Model forecasting platform.

The bottom line: - Antibody discovery services are moving from specialized support work to a bigger role in precision medicine and biologics development, with AI and automation now central to the next phase of growth.